IDiyas

For the Inventor, By the Inventor

San Diego, CA, United States of America

Michael B Shaghafi

USPTO Granted Patents = 15 

 

Average Co-Inventor Count = 4.1

ph-index = 4

Forward Citations = 45(Granted Patents)


Company Filing History:

goldMedal9 out of 506 
 
H. Lundbeck A/s
 patents
silverMedal4 out of 12 
 
Lundbeck La Jolla Research Center, Inc.
 patents
bronzeMedal2 out of 18 
 
Abide Therapeutics, Inc.
 patents

Years Active: 2018-2025

Loading Chart...
Loading Chart...
15 patents (USPTO):
1. 12378219 - Crystalline forms of a MAGL inhibitor (2025-08-05),
2. 11691975 - MAGL inhibitors (2023-07-04),
3. 11434222 - MAGL inhibitors (2022-09-06),
4. 11332453 - MAGL inhibitors (2022-05-17),
5. 11214557 - MAGL inhibitors (2022-01-04),
6. 11161856 - Spirocycle compounds and methods of making and using same (2021-11-02),
7. 11149037 - Pyrazole MAGL inhibitors (2021-10-19),
8. 11142526 - Spirocycle compounds and methods of making and using same (2021-10-12),
9. 11059822 - MAGL inhibitors (2021-07-13),
10. 10899737 - Piperazine carbamates and methods of making and using same (2021-01-26),
11. 10781211 - Spirocycle compounds and methods of making and using same (2020-09-22),
12. 10570106 - MAGL inhibitors (2020-02-25),
13. 10519134 - Pyrazole compounds and methods of making and using same (2019-12-31),
14. 10093635 - MAGL inhibitors (2018-10-09),
15. 10030020 - Spirocycle compounds and methods of making and using same (2018-07-24),

Title: The Innovative Contributions of Michael B. Shaghafi

Introduction

Michael B. Shaghafi is a prominent inventor based in San Diego, California. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds that modulate the activity of monoacylglycerol lipase (MAGL). With a total of 15 patents to his name, Shaghafi's work has the potential to impact pain management therapies.

Latest Patents

Among his latest patents is the development of crystalline forms of a MAGL inhibitor. This patent describes crystalline forms of the MAGL inhibitor 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(pyridazin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate. Additionally, he has worked on MAGL inhibitors that include spirocyclic and fused bicyclic carbamates. These compounds and their pharmaceutical compositions are designed to serve as effective modulators of MAGL, offering promising avenues for the treatment of pain.

Career Highlights

Shaghafi has had a notable career, working with reputable organizations such as H. Lundbeck A/S and Lundbeck La Jolla Research Center, Inc. His experience in these companies has allowed him to refine his expertise in drug development and innovation.

Collaborations

Throughout his career, Shaghafi has collaborated with talented individuals, including Cheryl A. Grice and Daniel J. Buzard. These collaborations have contributed to the advancement of his research and the successful development of his patented inventions.

Conclusion

Michael B. Shaghafi's innovative work in the field of MAGL inhibitors showcases his dedication to advancing pharmaceutical science. His contributions have the potential to significantly improve pain management therapies, making him a noteworthy figure in the realm of inventors.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…